分子病理风险分级评估WHO1级脑膜瘤生物学行为及患者预后OACSTPCD
Molecular Pathological Risk Grade Evaluates Biological Behavior and Prognosis of Patients with WHO Grade 1 Meningiomas
目的 探讨分子病理分级与WHO1级脑膜瘤复发、恶性进展以及患者生存的关系.方法 收集我科行手术治疗的WHO1级脑膜瘤病例资料及石蜡包埋切片.采纳Maas等建议的分子病理风险分级方法将本组病例分为低危、中危及高危级.先行Log rank单因素分析,继行Cox回归多因素分析,判断上述风险分级与患者无症状生存期(PFS)、恶性进展期(MPFS)以及总生存期(OS)的关系.结果 共198例资料完整的WHO1级病例,分子病理评估为低危级152例(76.8%),表现为无1p缺失;中危级42例(21.2%),其中1p缺失18例,1p合并6q缺失10例,1p合并14q缺失14例;高危级4例(2%),其中TERT启动子突变2例,CDKN2A/B纯合缺失1例,1p、6q、14q联合缺失1例.多因素分析显示分子病理风险级别与患者PFS(HR:0.029,95%CI:0.011~0.080)、MPFS(HR:0.032,95%CI:0.004~0.274)以及OS(HR:0.074,95%CI:0.032~0.174)显著负相关(P<0.05).结论 组织学1级脑膜瘤生物学行为仍具异质性,进一步的分子病理风险分级可更精准反映其生物学行为并评估患者预后.
Objective To explore the correlation of molecular pathological grading with WHO grade 1 meningioma recurrence,malignant progression,and patients'survival.Methods The medical records and paraffin-embedded tissues of patients with surgically resected WHO grade 1 meningioma were collected.The molecular pathological risk grading suggested by Maas et al.was adopted,and the patients were graded as low,intermediate,and high risk.Univariate log-rank test and multivariate Cox regression analyses were performed to determine the relationship between molecular risk grading and patient progression-free survival(PFS),malignant progression-free survival(MPFS),and overall survival(OS).Results Among 198 patients,152(76.8%)were graded as low risk,showing no 1p deletion;42(21.2%)patients were graded as intermediate risk,including 18 patients with 1p deletion,10 patients with 1p combined with 6q deletion,and 14 patients with 1p combined with 14q deletion;and 4(2%)patients were graded as high risk,including two patients with TERT promoter mutation,one patient with CDKN2A/B homozygous deletion,and one patient with 1p,6p,and 14q combined deletion.Multivariate analysis showed that molecular risk grading was negatively associated with PFS(HR:0.029,95%CI:0.011-0.080),MPFS(HR:0.032,95%CI:0.004-0.274),and OS(HR:0.074,95%CI:0.032-0.174;P<0.05).Conclusion The biological behavior of histological grade 1 meningiomas still exhibits heterogeneity,and further molecular pathological risk grading can more accurately reflect their biological behavior and evaluate patient prognosis.
曾令成;厉华;陈如东;杨洪宽;陈坚;于加省
430030 武汉,华中科技大学同济医学院附属同济医院神经外科
临床医学
脑膜瘤分子病理生存
MeningiomaMolecular pathologyPrognosis
《肿瘤防治研究》 2024 (006)
455-461 / 7
评论